Navigation Links
RECOVER Analyses Highlighted Need to Address Motor, Sleep and Other Non-Motor Symptoms of Parkinson's Disease
Date:4/13/2011

or symptoms, as measured by UPDRS III, and non-motor symptoms, as measured by PDNMS scores at baseline (r=0.35, p<0.0001), and end of maintenance (EoM) treatment (r=0.38, p<0.0001), and small correlations between change from baseline to EoM between UPDRS III and PDNMS scores (r=0.32, p<0.0001)
  • Small correlations between severity of early morning motor symptoms, as measured by UPDRS III, and nocturnal sleep disturbances, as measured by PDSS-2 total scores; Pearson correlation coefficients for UPDRS III and PDSS-2 total scores were 0.26 (p<0.0001) at baseline, 0.30 (p<0.0001) at EoM, and 0.36 (p<0.0001) for change from baseline to EoM.

  • Rotigotine provided long-term efficacy and tolerability

    Results from an open-label extension of a 6 month, Phase III, randomized, double-blind, placebo- and ropinirole-controlled trial (mean total duration 45+23 months) showed that rotigotine was generally well tolerated and that UPDRS motor and daily activity scores (UPDRS II+III) remained improved, compared to baseline, for over 4 years of treatment. This open label study enrolled 380 patients.

    Rotigotine plasma levels remained stable following transdermal patch removal and new patch application

    Mean trough plasma concentrations of rotigotine generally remained stable throughout a 4-month investigation of the effects of daily patch replacement on rotigotine plasma concentrations in 56 patients with advanced Parkinson's disease, taking part in a large multinational trial.

    About Neupro® in Europe

    Neupro® (rotigotine) is approved in the European Union for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effe
    '/>"/>

    SOURCE UCB
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
    2. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
    3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
    4. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
    5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
    6. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
    7. Portable CT Increases Chance of Stroke Survival and Recovery
    8. Statins Lower Stroke Severity, Improve Recovery
    9. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
    10. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
    11. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
    (Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
    (Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
    Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
    ... Amgen (Nasdaq: AMGN ) reported revenue unchanged ... $3,812 million for the third quarter of 2009. ... the third quarter of 2010 compared to $1,518 million for ... income was driven by unusually low research and development (R&D) ...
    ... 25 See video from Novartis: ... New Phase III data indicate that Menveo® (Meningococcal ... demonstrated robust immunogenicity in infants potentially offering protection ... 3. These data were presented during an oral ...
    Cached Medicine Technology:Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 2Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 3Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 4Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 5Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 6Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 7Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 8Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 9Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 10Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 11Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 12Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 13Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 14Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 15
    (Date:8/1/2015)... Los Angeles, CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered ... pop up when you hear the word “Karma.” , Vedic tradition, which gave birth ... and Karma is one of the central concepts of this tradition. According to the wisdom ...
    (Date:8/1/2015)... Uniondale, NY and Greenwich, CT (PRWEB) , ... ... ... Therapy (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired ... and Connecticut — incorporating it into its portfolio of state-of-the-art clinics. , “Our ...
    (Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
    (Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s ... biggest day each year is the Super Bowl. In the two weeks that separate the ... the host venue. The 2016 Super Bowl game will mark the 50th time it has ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
    Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
    ... Whether enjoying a meal at,home, at work or ... conscious,but don,t want to sacrifice great taste ... or ... The leader in the frozen sandwich category has,found the ... goodness,of whole grains in every bite with seven delicious ...
    ... 17 AIDS Healthcare,Foundation (AHF) today strongly criticized ... latest budget package drafted by Congress in order,to ... spending target for,next year. The fiscal year 2008 ... the House today and is,expected to be introduced ...
    ... for MammaPrint(R), AMSTERDAM, Netherlands, Dec. 17 ... of molecular diagnostics, announced,today that its MammaPrint(R) breast ... tool to assess risk of breast cancer recurrence ... at the,AACR/NCI/ EORTC conference "Molecular Targets and Cancer ...
    ... Dec. 17 The board of directors,of Eli Lilly and ... in its quarterly dividend. The board declared a dividend for ... common stock. This,raises the annual indicated rate to $1.88 per ... has increased the dividend payment., The dividend is payable ...
    ... 17 Many medications,reduce the risk of bone ... used drugs - bisphosphonates- have not been proven ... funded by the Agency for,Healthcare Research and Quality ... Human Services., The AHRQ report compared the ...
    ... the University of Pennsylvania School of Veterinary Medicine ... chemical dioxin attacks the cellular machinery, disrupts normal ... The team identified for the first time that ... nutrients into cellular fuel, are the target of ...
    Cached Medicine News:Health News:A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties 2Health News:A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties 3Health News:Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF 2Health News:Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF 3Health News:MammaPrint(R) Breast Cancer Test Shown To Be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients 2Health News:MammaPrint(R) Breast Cancer Test Shown To Be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients 3Health News:Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best 2Health News:Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best 3Health News:Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: